Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | CXCR4 | P61073 | 14/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2509468 | 0.81 | CXCR4 (0.39) | CXCR4 | |
| SCHEMBL4761081 | 0.81 | HDAC1 (0.39) | HDAC1HDAC6CXCR4SLC40A1CYP2D6 | |
| SCHEMBL7074107 | 0.76 | HDAC1 (0.39) | HDAC1HDAC6CXCR4CYP3A4CYP2D6 | |
| SCHEMBL7069357 | 0.75 | CXCR4 (0.44) | CXCR4SLC40A1CYP2D6 | |
| SCHEMBL30486101 | 0.75 | HDAC1 (0.52) | HDAC1HDAC6CXCR4ADORA2ACYP3A4 | |
| SCHEMBL29067448 | 0.75 | HDAC1 (0.52) | HDAC1HDAC6CXCR4ADORA2ACYP3A4 | |
| SCHEMBL7068193 | 0.75 | CXCR4 (0.42) | HDAC1HDAC6CXCR4CYP3A4CYP2D6 | |
| SCHEMBL14275061 | 0.74 | HDAC1 (0.51) | HDAC1HDAC6CXCR4CYP3A4CYP2D6 | |
| SCHEMBL5100363 | 0.73 | CXCR4 (0.46) | CXCR4SLC40A1CYP2D6 | |
| SCHEMBL3736077 | 0.73 | HDAC1 (0.54) | HDAC1HDAC6CXCR4ADORA2ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220341-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220341-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | HDAC1 1094/4885HDAC6 1371/4885CXCR4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.